Barcelona, Spain – 29 Aug 2017: A study in Japanese patients with diabetic retinopathy has questioned the benefit of treat-to-target intensive versus standard statin therapy. The late-breaking results from the EMPATHY trial are presented today in a Hot Line LBCT Session at ESC Congress. (1)
The challenge of preventing cardiovascular disease is aggravated by the sharp worldwide increase in diabetes, which is known to be a major risk factor for cardiovascular events. Better treatment options for preventing cardiovascular disease are needed, particularly in very high risk patients such as those with diabetic complications.
“The correlation between lower low-density lipoprotein (LDL) cholesterol and reduced risk of cardiovascular events has spurred interest in a treat-to-target approach in which the drug dose is adjusted to achieve a specific LDL cholesterol target,” said principal investigator Prof Hiroshi Itoh, of the Keio University School of Medicine, Tokyo, Japan. “However, the usefulness of the treat-to-target approach is controversial because of insufficient evidence.”
The EMPATHY (2) trial focused on preventing a first cardiovascular event in patients with diabetic retinopathy, an advanced stage of diabetes with particularly high risk of cardiovascular events. It is the first study to evaluate the effectiveness of intensive versus standard statin therapy in a treat-to-target approach in this high risk population.
The prospective trial included 5 042 patients with hypercholesterolaemia, diabetic retinopathy, and no history of coronary artery disease from 772 hospitals and family practice clinics across Japan.
Patients were randomly assigned in a one to one fashion to intensive or standard statin monotherapy with any statin for a maximum of 5.5 years. The LDL cholesterol target was below 70 mg/dL for intensive therapy and 100 to 120 mg/dL for standard therapy. The primary endpoint was the combined incidence of cardiovascular events or death from cardiovascular events. (3) Patients were followed up for an average of 37 months.
The investigators found that the primary endpoint was not significantly reduced by intensive statin therapy (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.67–1.07; p=0.15). However, the study showed that intensive therapy significantly reduced the secondary endpoint of cerebral events (cerebral infarction or cerebral revascularisation) (HR, 0.52; 95% CI, 0.31–0.88; p=0.01), particularly cerebral infarction (HR, 0.54; 95% CI, 0.32–0.90; p=0.02).
Prof Itoh said: “The actual difference in LDL cholesterol between the two groups was smaller than planned (27.6 mg/dL), which may be one reason that the trial could not meet the primary endpoint.”
Unlike the results from Western trials, the EMPATHY trial showed no significant reduction of cardiac events. “This may be due in part to the low number of cardiac events in the study,” said Professor Itoh. “During 5.5 years of follow-up there were more cerebral events than cardiac events, which is typical of Asian populations.”
Post-hoc analysis in subgroups of patients who achieved their LDL cholesterol targets showed that the primary endpoint was significantly reduced by intensive statin-based lipid lowering (HR, 0.48; 95% CI, 0.28–0.82; p=0.007).
“Our subanalysis findings suggest that it may be critically important for high risk patients to reach a target LDL cholesterol of less than 70 mg/dL,” said Prof Itoh. “We need further research to confirm whether this intensive target is truly useful, and if so, how to make that treatment goal accessible to more patients in a clinical setting.”
Sources of funding: Shionogi & Co., Ltd.
Disclosures: Prof Itoh has research contracts at Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Ltd., Taisho Toyama Pharm.Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Teijin Pharma Limited, Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and received consulting fee from Nipro Corporation., SBI Pharmaceuticals Co., Ltd.
References and notes:(1) The study “Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study” will be presented during:• The press conference Hot Line - Late Breaking Clinical Trials 4 on Monday 28 August from 13:00 to 14:00.• The session Hot Line - Late Breaking Clinical Trials 4 on Tuesday 29 August from 08:30 to 10:00 in Barcelona – Main Auditorium.(2) EMPATHY: standard versus intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY(3) Cardiovascular events included: 1) Cardiac events: myocardial infarction or unstable angina requiring unscheduled hospitalisation or coronary revascularisation, 2) Cerebral events: cerebral infarction or cerebral revascularisation, 3) Renal events: initiation of chronic dialysis, increase in serum creatinine level by at least two-fold, 4) Vascular events: aortic disease or peripheral artery disease.
ESC Press OfficeFor more information, please contact the ESC Press Office: firstname.lastname@example.org.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at email@example.com.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved